The proliferation and differentiation of lymphocytes varies with different concentrations of different antigens. The ability of B cells to respond to various antigens in a specific and sensitive manner is achieved through the use of low-affinity antigen receptors. The CD19 protein assembles with the B lymphocyte receptor to lower the threshold of antigen receptor-dependent stimulation. CD19 is expressed on follicular dendritic cells and B cells. The expression of CD19 runs through the entire development process of B cells, but it is not expressed on the surface of mature plasma cell membranes. Since CD19 is a marker of B cells, CAR-T targeting CD19 has shown shocking efficacy in the treatment of malignant B lymphocyte tumors. CAR-T constructed with FMC63 antibody (targeting CD19 murine monoclonal antibody) sequence has become the world's first CAR-T cell drug to be marketed . This product is a second-generation CAR lentiviral expression vector targeting CD19 with FMC63 as the scFv sequence.

Product name: Lenti-EF1a-CD19-3nd-CAR-EGFRt

Promoter: EF1a ^[1]

Intracellular co-activation signal: 4-1BB/CD28/CD3Zata

Resistance gene: Amp

Tag: EGFRt ^[2]

Remarks:

1. Compared with the CMV promoter, EF1a can be continuously expressed in immune cells, so it can significantly extend the expression of CAR in T cells.

2.  EGFRt intercepts domain III and domain IV of wild-type EGFR. This truncated EGFRt has no intracellular signal and will not transmit other signals to T cells . At the same time, these two domains are cetuximab Recognizing the epitope and expressing the epitope on T cells can not only serve as a CAR-T screening marker, but also add a safety switch for clinical research. Related flow cytometry antibodies can be inquired ( iCareAb, CAT# IAB001A )